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Cellular Biology
Plasminogen Activator Inhibitor-1 Regulates Myoendothelial
Junction Formation
Katherine R. Heberlein, Adam C. Straub, Angela K. Best, Mark A. Greyson, Robin C. Looft-Wilson,
Poonam R. Sharma, Akshaya Meher, Norbert Leitinger, Brant E. Isakson
Rationale: Plasminogen activator inhibitor-1 (PAI-1) is a biomarker for several vascular disease states; however, its
target of action within the vessel wall is undefined.
Objective: Determine the ability of PAI-1 to regulate myoendothelial junction (MEJ) formation.
Methods and Results: MEJs are found throughout the vasculature linking endothelial cells (ECs) and vascular
smooth muscle cells. Using a vascular cell coculture we isolated MEJ fractions and performed two-dimensional
differential gel electrophoresis. Mass spectrometry identified PAI-1 as being enriched within MEJ fractions,
which we confirmed in vivo. In the vascular cell coculture, recombinant PAI-1 added to the EC monolayer
significantly increased MEJs. Conversely, addition of a PAI-1 monoclonal antibody to the EC monolayer reduced
the number of MEJs. This was also observed in vivo where mice fed a high fat diet had increased PAI-1 and MEJs
and the number of MEJs in coronary arterioles of PAI-1/ mice was significantly reduced when compared to
C57Bl/6 mice. The presence of MEJs in PAI-1/ coronary arterioles was restored when their hearts were
transplanted into and exposed to the circulation of C57Bl/6 mice. Application of biotin-conjugated PAI-1 to the
EC monolayer in vitro confirmed the ability of luminal PAI-1 to translocate to the MEJ. Functionally,
phenylephrine-induced heterocellular calcium communication in the vascular cell coculture was temporally
enhanced when recombinant PAI-1 was present, and prolonged when PAI-1 was absent.
Conclusion: Our data implicate circulating PAI-1 as a key regulator of MEJ formation and a potential target for
pharmacological intervention in diseases with vascular abnormalities (eg, diabetes mellitus). (Circ Res. 2010;106:
1092-1102.)
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In diseases that exhibit vascular abnormalities, increasedcirculating plasminogen activator inhibitor-1 (PAI-1) is
considered a major biomarker; however its function in these
diseases remains unclear.1–5 In the vasculature, fibrinolysis
and the plasminogen activator (PA) system are regulated by
PAI-1 through inhibition of urokinase PA (uPA) and tissue
PA (tPA),6,7 maintaining an important balance between ma-
trix degradation and cellular adhesion. Inhibition of PAs
disrupts the activation of plasminogen into plasmin, nega-
tively regulating localized matrix degradation and maintain-
ing a stable scaffold for cells to adhere to.2,8–10 Decreases in
PAI-1 results in excessive proteolytic activity and increased
matrix degradation, creating an unstable extracellular matrix
(ECM) scaffold which disrupts cellular attachment and
thereby the invasion by endothelial cell (EC) extensions into
the ECM. Conversely, large increases in PAI-1 can inhibit
overall matrix degradation, preventing the growth of EC
extensions into the ECM.11,12 Therefore, the enzymatic bal-
ance of proteolytic activity and its regulation by PAI-1 is
important in the formation of EC cellular extensions.11,13,14
In the resistance vasculature, EC extensions that penetrate
the ECM-rich internal elastic lamina (IEL) form myoendo-
thelial junctions (MEJs), which are locations within a vessel
where ECs establish heterocellular contact or apposition with
vascular smooth muscle cells (VSMCs).15–17 The MEJ is
unique to the resistance vasculature and hypothesized to be a
highly organized cell-signaling microdomain that facilitates
heterocellular communication between ECs and VSMCs (for
review see18). Several additional studies correlate changes in
MEJ regulation with multiple vascular pathologies such as
diabetes mellitus, where changes in the vasoreactivity of
diseased vessels are associated with potential changes in the
number of MEJs.18–21 Despite the suggested importance of
MEJs in the maintenance of vasomotor tone, there are
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currently no documented mechanisms regarding the regula-
tion of MEJ formation and their potential role in vascular
pathologies.
To test the hypothesis that PAI-1 can regulate MEJ
formation we isolated in vitro MEJs and determined the
enriched expression of PAI-1 at the MEJ and confirmed its
presence at the MEJ in vivo. Modulation of PAI-1 activity at
the EC luminal surface was reflected by changes in both in
vitro and in vivo MEJ formation, where increases in PAI-1
augmented the number of MEJs and decreased PAI-1 activity
had the opposite effect. Heterocellular communication be-
tween the two cell types, presumably occurring at the MEJ
was also affected in response to changes in PAI-1 activity.
We therefore suggest that circulating PAI-1 regulates MEJ
formation and can alter heterocellular signaling mediated
through MEJs in the resistance vasculature.
Methods
An expanded Methods section is available in the Online Data
Supplement at http://circres.ahajournals.org.
Mice
Wild-type mice, strain C57Bl/6 and PAI-1/ mice, strain
B6.129S2-Serpine1tm1Mlg/J, were males 8 to 10 weeks of age and
used according to the University of Virginia Animal Care and Use
Committee guidelines. Mice used for high fat comparison were
C57Bl/6 mice fed a caloric-rich diet (5.45 kcal/g, 0.2% cholesterol,
35.5% fat; Bio-Serv).
Vascular Cell Coculture
Vascular cell cocultures were assembled as described.22 Cells were
derived from human umbilical vein (Cell Applications, Inc, San
Diego) and grown in M199 (Gibco) supplemented with 10% FBS
(Gibco), 1% glutamine (Gibco), 1% penicillin/streptomycin (Gibco),
EC media also contained endothelial cell growth supplement (5
g/mL, BD Biosciences); Additional cell lines were derived from
human coronary artery (Lonza Walkersville Inc). Endothelial cells
were grown in EBM-2 MV (Lonza) supplemented with Lonza bullet
kits (Lonza), VSMCs were grown in SmBM (Lonza) supplemented
with Lonza bullet kits (Lonza). Seeding densities of 7.5x104 VSMCs
and 3.6x105 ECs were used.
Recombinant PAI-1 (rPAI-1) (0.1 g/mL; Technoclone) and
PAI-1 monoclonal antibody (mAb) (10 g/mL; Technoclone) were
added every 24 hours to ECs 48 hours before isolation. Biotin-
conjugated rPAI-1 (Cell Sciences) was added to ECs 30 minutes
before isolation.
Isolation of MEJ Fractions
Following 6 days in culture, VSMC monolayers were scraped into
lysis buffer and repeated for EC monolayers. The MEJ fractions
were collected by removing the denuded Transwell membranes into
lysis buffer, and vortexing. All fractions were sonicated and spun at
2500 rpm for 5 minutes and the supernatant collected. All steps were
performed at 4°C.
Immunoblots
Protein fractions were run on 10% SDS-PAGE Gels, transferred to
nitrocellulose and imaged on a Li-Cor Odyssey Imager.23
Antibodies and Protein
Secondary antibodies: phalloidin conjugated to Alexa 488 or Alexa
594, donkey anti-rabbit or donkey anti-mouse Alexa 488 or Alexa
594, all from Invitrogen. Goat anti-rabbit or anti-mouse IRDye 680
or 800CW was used for immunoblots (Li-cor Biosciences). Primary
antibodies: SM-actin (monoclonal, Sigma); VE-cadherin, uPA and
tPA (all polyclonal, Santa Cruz Biotechnologies), GAPDH (mono-
clonal, Zymed), PAI-1 polyclonal (Abcam), PAI-1 monoclonal
(immunoblot analysis, BD Biosciences), Cx37 and Cx40 (poly-
clonal, ADI), Cx43 (polyclonal, Sigma) Cx45 (polyclonal, kind gift
of Steinberg, Washington University24), anti-rabbit 10 nm gold beads
were from The Jackson Laboratory.
2D-DIGE Analysis
Individual protein fractions were labeled with Cy2, Cy3 or Cy5 and
run per manufacturer specifications (Amersham BioSciences). IPG
strips were transferred into gradient SDS-Gel (9% to 12% SDS).
Image scans were made using Typhoon TRIO (Amersham Bio-
Sciences), analyzed by Image QuantTL software (GE-Healthcare).
The ratio change of protein differential expression was obtained by
in-gel DeCyder software analysis.
Mass Spectrometry
Proteins of interest were digested in-gel and MALDI-TOF MS and
TOF/TOF tandem MS/MS were performed. Peptide mass and
associated fragmentation spectra were searched in the National
Center for Biotechnology Information nonredundant (NCBInr) da-
tabase. Candidates with protein score confidence interval percent
(C.I.%) or Ion C.I.% greater than 95 were considered significant.
Immunostaining
Immunohistochemistry on the vascular cell coculture (VCCC) was
performed as described.22
Quantification of MEJs Using the VCCC
The number of F-actin filled pores per micrometer was quantified
using Metamorph (Universal Imaging Corps, version 7.5.6.0). Phal-
loidin staining visualized F-actin within pores of the Transwell.
Immunolabeling on TEM Sections
Visualization of proteins by TEM was performed as described.25
Quantification of electron-dense gold-beads was performed by im-
munolabeling for PAI-1 with minimum 5 TEM images per coronary
arteriole, 10 m apart. The areas of each component (EC, MEJ, and
VSMC) were quantified using Metamorph software calibrated to
measuring area (m2). The EC and VSMC monolayers were traced
from apical to basal lateral membrane. For MEJs, cellular extensions
penetrating the IEL were defined by a line across the basal lateral
membrane from which the MEJ originated, dissecting the junction
from the monolayer, tracing the extension through the IEL to the
base of the adjacent basal lateral membrane. The area inside these
lines defined the area of the MEJ. The number of gold beads in each
area (EC, MEJ, or VSMC) was counted. Measurements represent the
average number of beads per micron squaredSE.
Non-standard Abbreviations and Acronyms
EC endothelial cell
ECM extracellular matrix
IEL internal elastic lamina
mAb monoclonal antibody
MEJ myoendothelial junction
PAI-1 plasminogen activator inhibitor-1
PE phenylephrine
rPAI-1 recombinant plasminogen activator inhibitor-1
tPA tissue plasminogen activator
uPA urokinase plasminogen activator
VSMC vascular smooth muscle cell
VCCC vascular cell coculture
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Quantification of PAI-1 on Actin Bridges In Vivo
Quantification of PAI-1 on actin bridges formed between ECs and
VSMCs in vivo was performed as previously described.25
Ultrastructure Electron Microscopy
Coronary arterioles were fixed in 4% paraformaldehyde and 2%
gluteraldehyde at 4°C and ultrastructural TEM images were obtained
as described.3 We quantified the total number of MEJs within a
vessel using a minimum of 5 TEM images per coronary arteriole. To
quantify the radial length of a vessel, a single line was traced along
the EC basal lateral membrane with this distance measured using
calibrated Metamorph software. Cellular extensions that penetrated
the traced EC basal lateral membrane, IEL and came within 250
nm of membranous contact between ECs and VSMCs was counted
as one MEJ. Numbers represent the average number of MEJs per
10 m radial length  SE. A minimum radial diameter of 150 mm
per mouse and 10 m between each TEM section were used.
Heart Transplants
Heart transplants were performed as described (see Online Figure
I).26 Five days postsurgery, donor hearts were harvested for TEM.
Recombinant PAI-1 Tail Vein Injections
Fifty microliters (L) of rPAI-1 (1000 ng/g) or saline was injected
into PAI-1/ mice via lateral tail vein every 12 hours for five days.
Tissue was harvested for TEM.
Calcium Imaging
Fura-2 acetoxymethyl ester was loaded onto EC and VSMC mono-
layers as described for Fluo-4 acetoxymethyl ester (see Online
Figure II).27 The VSMCs were stimulated with 10 mol/L phenyl-
ephrine (PE) and EC intracellular calcium concentrations [Ca2]i
were recorded as described.27
Statistics
Significance for all experiments was at P0.05 and determined by
one-way ANOVA (Bonferroni post hoc test); error bars are SE
using Origin Pro 6.0 software.
Results
Isolation and Characterization of MEJ Proteins
For initial experiments demonstrating isolation of EC,
VSMC, and MEJ protein fractions we used phalloidin to mark
cellular components of the VCCC. In Figure 1A and 1D, an
intact VCCC with cell monolayers and actin extensions
within the pores of the Transwell (eg, in vitro MEJs22) is
clearly observed. The formation of junctions is also con-
firmed by expression of vascular specific connexins in
isolated VSMC, EC, and MEJ fractions (as previously de-
scribed22 and Online Figure III). After the EC and VSMC
monolayers were removed by scraping, the actin extensions
within the Transwell pores remained (Figure 1B and 1E).
When the scraped membranes were vortexed with lysis
buffer, in vitro MEJs were no longer visible via phalloidin
staining (Figure 1C and 1F). The three fractions were ana-
lyzed via silver stain (Figure 1G) and GelCode Blue (Figure
1H), demonstrating an abundance of proteins in each fraction.
Immunoblots demonstrated labeling of MEJ and EC fractions
for VE-Cadherin (Figure 1I) and SM-actin labeling of
VSMC and MEJ fractions (Figure 1J), with equivalent
loading for all three fractions (Figure 1K). These data
demonstrate our ability to isolate in vitro MEJs from the
VCCC.
Simultaneous comparison of isolated in vitro VSMC, EC,
and MEJ fractions was performed using 2D-DIGE proteomic
analysis. Representative images compare EC and VSMC
fractions (Figure 2A, top), MEJ and VSMC fractions (Figure
2A, middle) and MEJ and EC fractions (Figure 2A, bottom)
from the same gel. Gel images for each fraction were
obtained and overlaid, allowing direct quantitative compari-
Figure 1. Isolation of MEJ protein frac-
tions from vascular cell coculture. Con-
focal microscopy of VCCC stained with
phalloidin en face (A through C) and
transverse (D through F). Conditions
shown include unscraped membranes
viewed en face (A) and transverse (D)
scraped membranes viewed enface
(B) and transverse (E), as well as scraped
and lysed membranes viewed en face (C)
and transverse (F). SDS-PAGE of VSMC,
EC, and MEJ fractions stained with
GelCode Blue (G) and silver stain (H). Im-
munoblots of protein fractions probed for
VE-Cadherin (I), SM-actin (J), and
GAPDH (K). Bar in A is 20 m and repre-
sentative for A through C; bar in D is
10 m and representative for D through
F. Arrows in A and B indicate pores of
the Transwell insert.
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son between each fraction of the same spot. Using Qualitative
DeCyder analysis, all spots with increased protein expression
in the MEJ fraction were identified. Of these, three spots
(arrows 1 to 3) of similar molecular weight and pH had
greater than 2.5 fold increase in protein expression in the MEJ
fraction as compared to VSMC and EC fractions (Figure 2A).
Using DeCyder software, spots 1 to 3 are represented quan-
titatively as protein expression peaks, where each spot is
identified by a magenta tracer (Figure 2B). Mass spectrom-
etry identified each of these spots as PAI-1, with minimal
99.9% confidence in protein identification (Figure 2C). It is
likely, although not confirmed that each spot represents a
separate glycosylation isoform of PAI-1. Results were con-
firmed using coronary artery EC, VSMC, and MEJ fractions
(Online Figure IV).
PAI-1 at the MEJ
To verify expression of PAI-1 at the MEJ in vitro, we
immunoblotted isolated VSMCs, EC and MEJ fractions and
showed enrichment of PAI-1 in MEJ fractions (Figure 3A).
Using confocal microscopy to image transverse sections of
the VCCC, we also confirmed the expression of PAI-1 in the
pores of the VCCC membrane, where PAI-1 colocalized with
F-actin regardless of it’s location in the Transwell pores
(Figure 3B). Associated substrates for PAI-1, active and
inactive uPA, but not tPA, were increased in MEJ fractions
(Online Figure V), supporting our identification of PAI-1 at
the MEJ in vitro. Quantified immunohistochemistry of whole
mount tissue preps from fixed C57Bl/6 and PAI-1/ mes-
enteric, cremasteric and coronary microvascular beds labeled
for PAI-1 confirm the presence of PAI-1 on actin bridges in
vivo (Figure 3C). Quantified immunolabeling for PAI-1 on
TEM sections of C57Bl/6 coronary arterioles showed expres-
sion of PAI-1 at the MEJ in vivo (Figure 3D, as well as
mesenteric and cremasteric arterioles, Online Figure VI).
The presence of PAI-1 is crucial for invasion of EC
extensions into the ECM.13 To determine whether PAI-1 is
similarly necessary for the formation of MEJs, we depleted
PAI-1 activity in each monolayer using a PAI-1 specific mAb
or increased PAI-1 activity using rPAI-1. Depletion of
Figure 2. 2D-DIGE analysis of isolated MEJ protein fractions from vascular
cell coculture. 2D-DIGE blots of isolated protein fractions from the VCCC. Illus-
trative schematics in A represent the compared fractions for each gel image as
they occur in the VCCC. Conditions include comparison of ECs (red) to VSMCs
(green), (A, top); MEJ (red) to VSMCs (green) (A, middle); and MEJ (red) to ECs
(green) (A, bottom). Arrows labeled 1 to 3 in A indicate 3 spots representing a
unique protein with greater than 2.5-fold increase in fluorescent intensity (ie,
protein expression) in the MEJ vs VSMC and EC fractions. Using Quantitative
DeCyder analysis, spots 1 to 3 are represented in a 3D visualization for each
spot of interest and identified by a magenta tracer (B), indicating protein fluores-
cent intensity peaks in VSMC, MEJ, and EC fractions. The mass spectrum of spots
1 (C, top), 2 (C, middle), and 3 (C, bottom) identified each spot as plasminogen activator inhibitor-1. For all images, n30 Transwells.
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activity caused a significant reduction in MEJs, but only
when applied to EC or EC/VSMC monolayers (Figure 4A
and Online Figure VII). Likewise, addition of rPAI-1 caused
a significant increase in MEJs only in the EC and EC/VSMC-
treated monolayers (Figure 4B and Online Figure VII). The
identification of PAI-1 was corroborated in coronary artery
cells with immunoblots for PAI-1 at the MEJ as well as
changes in MEJ formation in response to changes in PAI-1
(Online Figure VII).
To verify the ability of PAI-1 to regulate MEJ formation in
vivo, we performed TEM ultrastructure analysis on coronary
arterioles isolated from C57Bl/6 and PAI-1/ mice. Vessels
from C57Bl/6 mice had significantly more MEJs (Figure 5A
and 5I) than those from PAI-1/ mice (Figure 5B and 5I).
This was also demonstrated in mesenteric and cremasteric
arterioles (Online Figure VIII). Conversely, coronary arte-
rioles isolated from C57Bl/6 mice fed a high fat diet had
increased PAI-1 expression (Online Figure IX) and signifi-
Figure 3. Localization of PAI-1
at the MEJ. Immunoblots of
VSMC, EC, and MEJ fractions
isolated from the VCCC blotted
for PAI-1 and GAPDH as a load-
ing control. Normalized quantifi-
cation of protein expression for
PAI-1 in each fraction is given in
the adjacent histogram, n4 (A).
Immunocytochemistry of a single
focal plane of a transverse sec-
tion of the VCCC labeled for
PAI-1 (green) and actin (red; phal-
loidin) demonstrate colocalized
expression of both proteins
regardless of the location in the
Transwell pores (B). In vivo, the
expression of PAI-1 on actin
bridges that form between ECs
and VSMCs (ie, MEJs) in mesen-
tery, cremaster and coronary
microvascular beds is quantified
using confocal microscopy in
both C57Bl/6 and PAI-1/ mice,
n3 mice per experimental para-
digm, 5 images per mouse (C). A
representative TEM image of a
MEJ from a mouse coronary
arteriole labeled for PAI-1 with 10
nm gold particles is shown and
quantified as number of beads
per micrometer squared in D,
n3 mice per experimental para-
digm, 5 images per mouse.
Enlargement of white box in B is
shown on right. In C, arrow indi-
cates PAI-1 labeling. In D, “L”
indicates lumen. Enlargement of
red box insert in D is shown on
right. Bar in B is 5 m; bar in D
is 0.5 m. *P0.05.
Figure 4. Effects of PAI-1 on MEJ for-
mation in vitro. Metamorph analysis of
changes in the number of MEJs per mi-
crometer following inhibition of PAI-1
activity by application of 10 g/mL PAI-1
specific mAb to the EC, EC and VSMC,
or VSMC monolayers is shown in A. Anal-
ysis of changes in the number of MEJs
per micrometer following increases in
PAI-1 activity by application of 0.1 g/mL
rPAI-1 to the EC, EC and VSMC, or
VSMC monolayers is shown in B.
*P0.05. For each condition (A and B),
n7 Transwells per condition, 10 images
per Transwell.
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cantly more MEJs (Figure 5C and 5I) as compared to
C57Bl/6 mice fed a standard chow diet. To test whether
circulating PAI-1 could enhance MEJ formation in vivo, we
performed heterotypic heart transplants. Transplantation of a
C57Bl/6 heart into a C57Bl/6 mouse (Figure 5D) or a
PAI-1/ heart into a PAI-1/ mouse (Figure 5E) produced
no change in MEJ formation (Figure 5A, 5B, 5I, respec-
tively). However, PAI-1/ hearts transplanted into a
C57Bl/6 mouse, increased MEJ formation similar to that seen
in C57Bl/6 mice (Figure 5F and 5I). This data further
suggests that circulating PAI-1 interacts with ECs to influ-
ence formation of MEJs. To verify that increases in MEJ
formation were attributable to increases in PAI-1, we injected
saline or rPAI-1 into PAI-1/ mice via tail vein, to increase
circulating PAI-1 (Online Figure X). Saline injected PAI-
1/ mice showed no change in MEJ formation (Figure 5G)
when compared to noninjected PAI-1/ (Figure 5A, 5B, and
5I). Increases in circulating PAI-1 (injected rPAI-1) produced
similar increases in MEJ formation (Figure 5H) as compared
to those seen following the heart transplants and C57Bl/6
mice (Figure 5A, 5E, and 5I) suggesting changes in MEJ
formation are likely attributable to PAI-1.
To determine whether exposing the EC luminal surface to
increased PAI-1 could result in relocation of PAI-1 to the
MEJ, we applied biotin-conjugated rPAI-1 to the VSMC or
EC monolayers of the VCCC thirty minutes before isolation.
Following application of biotin-conjugated rPAI-1 to the
VSMCs the rPAI-1 could not be detected with streptavidin in the
MEJ fractions, nor in the controls (Figure 6A through 6D).
However, when applied to the EC monolayer, the biotin conju-
gated rPAI-1 was readily detected at the MEJ (Figure 6A, 6B,
and 6E). The sum of the data suggests that increased PAI-1
results in the movement of PAI-1 from the lumen to the MEJ.
Effects of PAI-1 on Ca2 Signaling at the MEJ
To test the functional effect of changes in the number of MEJs
as a result changes in PAI-1 activity in vitro, we measured
heterocellular Ca2 communication from the VSMCs to the
ECs by stimulating VSMCs with PE (Figure 7A). Following
stimulation of the VSMCs with PE, there were no changes in
the maximum EC Ca2 response regardless of EC treatment
with rPAI-1(rPAI-1) or mAb to PAI-1(-PAI-1). The addi-
tion of gap junction blocker glycyrrhetinic acid (GA) or
inhibiting MEJ formation through collagen coating of the
Transwell (Online Figure XI) significantly decreased the EC
Ca2 response (Figure 7B). However, the addition of rPAI-1
to the EC monolayer resulted in a more rapid increase in EC
Ca2 as compared to EC monolayers with depleted PAI-1
(-PAI-1; Figure 7C and 7D). None of the conditions altered
the expression of vascular connexins at the MEJ (Online
Figure XII). These data suggest that PAI-1 can enhance
heterocellular communication, which is likely a result of
increased MEJ formation.
Discussion
In the present study we provide evidence for the biomarker
PAI-1 in the regulation of MEJ formation and function.
Plasminogen activator inhibitor-1 is the major regulator of the
PA system. Components of the PA system, uPA and tPA
activate plasminogen to plasmin, which degrades ECM.
Specifically, inhibition of uPA by PAI-1 decreases matrix
degradation, maintaining a localized area of structured matrix
scaffold to facilitate cellular invasion of EC extensions into
the ECM.11,28,29 Because of its role in the formation of
cellular extensions and regulation of matrix degradation,
disruption of the balance between PA components, namely
changes in PAI-1 activity, can result in decreased cellular
invasion. In the resistance vasculature, cellular invasion by
the ECs or VSMCs is required for functional MEJs to form.
The disruption of MEJ function has been indirectly impli-
cated in vascular diseases such as diabetes mellitus19–21;
however, no studies regarding regulation of MEJ formation
have been reported.
To identify regulatory proteins enriched at the MEJ, we
developed a method for isolating in vitro MEJ fractions using
the VCCC as an in vitro model of the MEJ.22,27,30 Isolation of
specific EC, VSMC, and MEJ protein fractions was con-
firmed using immunoblot analysis for cell-type specific
markers, which not only demonstrated successful isolation of
each monolayer, but isolation of the EC and VSMC compo-
nents of the MEJ as well. This is the first time that MEJs have
been directly isolated, either in vivo or in vitro and we believe
this method will enhance the capacity to investigate the
function of MEJs. Although a method to isolate protein from
MEJs in vivo would be ideal, thus far any method to isolate
and characterize MEJs outside of immunohistochemistry,
usually using TEM (eg, elsewhere16), has proven elusive.
Using simultaneous 2D-DIGE analysis, we identified three
spots representing proteins with increased expression in the
MEJ (in vitro) as compared to ECs and VSMCs and using
mass spectrometry these spots were determined to be PAI-1.
Expression of PAI-1 at the MEJ was confirmed both in vitro
using confocal microscopy and in vivo using TEM. Because
all three spots from the 2D-DIGE were found at the same
molecular weight but demonstrated different isoelectric fo-
cusing, it is possible that each spot represents one of the
glycosylated isoforms of PAI-1.31 It has been suggested that
the glycosylation state of PAI-1 may be useful in determining
the protein’s origin32 and further investigation regarding the
glycosylated isoforms of PAI-1 could provide insight for the
origin of PAI-1 expressed at the MEJ in vivo.
Because of the ability of PAI-1 to regulate matrix degra-
dation and cellular adhesion to the ECM, it is considered an
integral component of EC invasion into the ECM.11 We
therefore tested the hypothesis that MEJ formation mimics
EC invasion of the ECM as regulated by PAI-1. Using the
VCCC, increases in PAI-1 activity (by addition of rPAI-1)
promoted an increase in the number of actin extensions (ie, in
vitro MEJs) that formed. Conversely depletion of endogenous
PAI-1 activity (using a mAb specific for PAI-1) decreased the
number of actin extensions, suggesting PAI-1 plays a critical
role in the formation of MEJs. Correlating with these data,
TEM analysis of isolated PAI-1/ arterioles demonstrated
significantly less MEJs as compared to C57Bl/6 mice. Ultra-
structure analysis also revealed a thicker IEL in the knockout
vessels as compared to wild type. These data are in agreement
with recent evidence that shows PAI-1/ cells exhibit
increased collagen production, which correlates with an
Heberlein et al PAI-1 Regulates Myoendothelial Junctions 1097
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Figure 5. Effects of PAI-1 on MEJ formation in vivo. Ultrastructural TEM images of coronary arterioles at low magnification (top) and
higher magnification (bottom) from C57Bl/6 (A), PAI-1/ hearts (B), and C57Bl/6 fed a high-fat Western diet (C). TEM was used to
visualize MEJs in coronary arterioles for each of the following experimental paradigms: C57Bl/6 hearts transplanted into recipient
C57Bl/6 mice (D), PAI-1/ hearts transplanted into recipient PAI-1/ mice (E), and PAI-1/ hearts transplanted into recipient
C57Bl/6 mice (F). TEM analysis of coronary arterioles isolated from saline injected PAI-1/ mice (G) and rPAI-1 injected PAI-1/ mice
(E) are also shown. The number of MEJs per 10 m radially is quantified for images A through H in I. Bar in each low magnification
image (top image) is 2 m, bar in A (higher magnification, top) is 2 m and representative for all higher magnification images. In all
images, * denotes vessel lumen and for each image, the lumen is located above the EC monolayer. EC and VSMC monolayers are sep-
arated by IEL for all images; arrows indicate MEJ in each magnified image. In I, *P0.05 when compared to C57 animals. For images
A through F and H, n3 mice per experimental paradigm, 5 images per mouse. In G, n2 mice, 5 images per mouse.
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increase in TGF- activity through sustained activation by
integrins.33
Plasminogen activator inhibitor-1 is a biomarker for sev-
eral vascular disease states, including diabetes 1,3–5,34–36
which is also associated with the dysregulation of MEJs.18 In
C57Bl/6 mice fed a high fat diet there is a significant increase
in body weight, blood glucose and PAI-1 levels, effectively
mimicking diabetic conditions (Online Figure IX). Isolated
coronary arterioles from these mice have significantly more
MEJs and decreased IEL thickness as compared to the
C57Bl/6, so we determined if increases in circulating PAI-1
were capable of regulating MEJ formation in vivo using
heterotypic heart transplants. When hearts from PAI-1/
mice were transplanted into a C57Bl/6 mouse and exposed to
circulating PAI-1, MEJ formation within PAI-1/ coronary
arterioles was significantly increased five days post surgery.
We confirmed that changes in circulating PAI-1 affected MEJ
formation by injecting rPAI-1 into PAI-1/ mice, demon-
strating an increase in MEJ formation in isolated coronary
arterioles similar to that seen in PAI-1/ vessel transplanted
into a C57Bl/6 and C57Bl/6 controls. Evidence shows that
increases in available PAI-1 coincides with increased cellular
invasion37 and our data supports a similar mechanism,
whereby increases in MEJ formation occur in response to
circulating PAI-1.
Application of rPAI-1 in vitro and heterotypic heart trans-
plants suggest for the first time that increases in PAI-1 at the
EC luminal membrane can effect MEJ formation. The appli-
cation of biotin-conjugated rPAI-1 demonstrated the translo-
cation of biotin-conjugated rPAI-1 from the luminal surface
of ECs to the MEJ and further supports the hypothesized
movement of PAI-1. It is well documented that VSMCs
produce PAI-138,39 and it is likely that some of the endoge-
nous PAI-1 expressed at the MEJ is VSMC-derived, how-
ever, the application of biotin-conjugated rPAI-1 to the
VSMC monolayer showed no increase in PAI-1 at the MEJ,
which coincides with experiments that show with application
of mAb or rPAI-1 to the VSMC monolayer there is no change
in the number of MEJs in vitro. Therefore, our data indicates
that in conditions where circulating PAI-1 is increased,
changes in MEJ formation are mediated through the move-
ment of circulating PAI-1 from the luminal surface of ECs to
the IEL. Although the internalization of PAI-1 for degrada-
tion occurs via a low density lipoprotein receptor mediated
mechanism was first described in 199240,41, there is currently
no defined mechanism for the uptake and translocation of
circulating PAI-1 to areas of the IEL and subsequent sites of
potential MEJ formation.
As a unique signaling microdomain, the MEJ is hypothe-
sized to play a key role in the regulation of heterocellular
Ca2 signaling (reviewed elsewhere18). Modulation of PAI-1
activity in vitro using rPAI-1 or mAb to PAI-1 showed no
variation in the maximal EC Ca2 responses following PE
stimulation of VSMCs. This indicated that the ECs could still
respond normally to second messengers that are produced in
the VSMCs and move through gap junctions at the MEJ (eg,
elsewhere30,42). However, there was a significant difference in
the rate of Ca2 response between VCCCs treated with
rPAI-1 and those with depleted PAI-1, correlating with an
increase or decrease (respectively) in the number of MEJs
(Figure 7). We interpret these data to mean that the number of
MEJs, specifically gap junctions at the MEJ, dictates the time
necessary for ECs to respond to second messengers from the
VSMCs.
In concurrence with our Ca2 data and the observed effects
of PAI-1 on MEJ formation, we would hypothesize that mice
deficient in PAI-1 have impaired vasoreactivity to agonist
stimulation caused by a reduced number of MEJs. Indeed, it
was recently reported that mesenteric artery rings from
Figure 6. Uptake and expression of biotin-conjugated rPAI-1
at the MEJ. Immunoblots of VSMC, MEJ, and EC fractions iso-
lated from the VCCC stained with streptavidin. Three experi-
mental paradigms were tested: no application of biotin-
conjugated rPAI-1, application of biotin-conjugated rPAI-1 (0.1
g) to the VSMC monolayer and application of biotin-
conjugated rPAI-1 (0.1 g) to only the EC monolayer. GAPDH is
shown directly below each condition (A). Normalized quantifica-
tion of protein expression for biotin-conjugated rPAI-1 for each
fraction and experimental paradigm is given in B. Immunocyto-
chemistry on transverse sections of the VCCC for biotin-
conjugated rPAI-1 using streptavidin (green) and F-actin (with
phalloidin, red) for the following experimental paradigms: no
application of biotin-conjugated rPAI-1, application of biotin-
conjugated rPAI-1 (0.1 g) to the VSMC monolayer and applica-
tion of biotin-conjugated rPAI-1 (0.1 g) to only the EC mono-
layer). For all images, VCCC were treated 30 minutes before
isolation. Bar in C is 10 m and representative for images
(C and D). *P0.05. For A and B, n4.
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PAI-1/ mice have diminished sensitivity to acetylcholine
(R. Korthuis, University of Missouri, Columbia, unpublished
data, 2009). It is also well documented that in multiple
diabetic models with upregulated PAI-1, there is increased
sensitivity to vasoconstrictors (eg, PE).43–46 Our data supports
this hypothesis, providing a potential mechanism for how
PAI-1 may affect vasoreactivity through changes in MEJ
formation. However, it is important to note that despite
increasing evidence supporting a role for MEJs in patholog-
ical conditions, it is still unknown if these changes are
compensatory or promoting the disease state.
In conclusion, after isolating proteins expressed at the MEJ
and performing 2D-DIGE analysis, we have identified PAI-1,
an important mediator of ECM degradation and major bi-
omarker for several vascular diseases, as being enriched at the
MEJ. Our data suggests localization of PAI-1 to the MEJ
allows it to act as a key regulator of MEJ formation and
function. The increase or decrease in MEJs in response to
changes in PAI-1, including conditions that mimic diabetes,
correlate with altered temporal Ca2 responses in ECs fol-
lowing VSMC stimulation. Although this article does not
present a mechanism for how PAI-1 regulates MEJ forma-
tion, it is the first evidence of a protein inducing the formation
of MEJs, as is extensively demonstrated using innovative
techniques both in vitro and in vivo. Although it remains to be
seen if the changes in MEJ formation during vascular disease
are beneficial, the accumulation of this work suggests that
manipulation of PAI-1 at the MEJ may be an attractive
pharmaceutical target to treat vascular associated diseases
where heterocellular communication is aberrant.
Figure 7. Heterocellular Ca2 communication in vascular cell cocultures with increases and decreases in PAI-1 activity. Sche-
matic representing the setup for measuring EC [Ca2]i following PE stimulation of the VSMC (A). The maximum values of EC [Ca
2]i
following PE stimulation is quantified, and conditions include application of PAI-1 (rPAI-1); application of rPAI-1 plus glycyrrhetinic
acid (rPAI-1GA); control; controlGA, decreases in PAI-1 using a mAb against PAI-1 (-PAI-1); decreases in PAI-1 plus glycyrrhetinic
acid (-PAI-1GA); and no MEJs (B). In C, the temporal change in EC [Ca2]i after stimulation of VSMC with PE following application of
rPAI-1 (rPAI-1), control; decreases in (-PAI-1); and no MEJs are shown. The time required to reach maximum EC [Ca2]i fluorescent
intensity after VSMC stimulation with PE is shown for each condition: application of rPAI-1 (rPAI); control; and decreases in PAI-1
(-PAI-1) (D). For all images, VCCCs were treated for the final 48 hours of culture, *P0.05; n3 Transwells per experimental condition.
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Novelty and Significance
What Is Known?
● Plasminogen activator inhibitor-1 (PAI-1) is a major biomarker for a
variety of vascular pathologies and regulates the invasion of
cellular extensions into the extracellular matrix.
● Myoendothelial junctions (MEJs) link endothelial and vascular smooth
muscle cells and promote heterocellular communication within the
resistance vasculature.
● Myoendothelial junctions are hypothesized to be associated with
several vascular disease states.
What New Information Does This Article Contribute?
● PAI-1 expression is enriched at the MEJ in vitro and in vivo.
● The formation of MEJs is regulated by PAI-1 in vitro and in vivo and
effects heterocellular Ca2 signaling at the MEJ in vitro.
● In mice fed a diabetogenic diet, increases in circulating PAI-1 resulted
in increased MEJ formation.
Myoendothelial junctions (MEJs) are predominantly located
within the resistance vasculature and couple endothelial and
vascular smooth muscle cells within the vessel wall. The MEJs
are suggested to play a role in the regulation of vasoreactivity via
heterocellular communication and have been implicated in
several vascular diseases; however, how these structures are
regulated is currently unknown. The formation of cellular
extensions is governed by plasminogen activator inhibitor-1
(PAI-1), which is a major biomarker for microvascular diseases.
We have identified PAI-1 at the MEJ and show a direct
correlation between PAI-1 and the number of MEJs. We
demonstrate that PAI-1 directly regulates MEJ formation and
notably, we show there is an increase in MEJs in conditions that
mimic type II diabetes. Microvascular dysfunction associated
with type II diabetes can lead to hypertensive conditions and our
data show that increases in the number of MEJs results in
increased sensitivity to vasoconstrictors in vitro. In sum, these
data are the first to demonstrate the ability of a single protein to
regulate MEJ formation and provide a potential future pharma-
ceutical target for microvascular diseases associated with
increased PAI-1.
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